Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies-Reference-Cited by-同舟云学术

Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies

Published:2022-12 Issue:6 Volume:61 Page:103473
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Xu Qian-wen,Xu Hui,Xue Lei,Wang Li,Zhang Xu-han,Song Kai-di,Yao Wen,Wan Xiang,Tong Juan,Liu Hui-lan,Liu Xin,Zhu Xiao-yu,Sun Zi-min,Wang Xing-bing

Funder

Major Science and Technology Projects in Anhui Province

National Natural Science Foundation of China

Science and Technology Planning Project of Guangdong Province

Publisher

Elsevier BV

Subject

Hematology

Reference45 articles.

1. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group;Hunger;J Clin Oncol,2012

2. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century;Pulte;Blood,2009

3. The myth of the second remission of acute leukemia in the adult;Forman;Blood,2013

4. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011

5. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia;Porter;Sci Transl Med,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy;Anti-Cancer Drugs;2023-01-04